Hossein Borghaei, DO, MS

This Fox Chase professor participates in the Undergraduate Summer Research Fellowship.
Learn more about Research Volunteering.

Request an Appointment

Call 888-369-2427

Request Online

Clinical Locations

Fox Chase Cancer Center
333 Cottman Avenue
Philadelphia, PA 19111
Phone: 888-369-2427

Chief, Division of Thoracic Medical Oncology

Professor, Department of Hematology/Oncology

Co-Director, Immune Monitoring Facility

Gloria and Edmund M. Dunn Chair in Thoracic Oncology

Specialties

Thoracic Medical Oncology

Areas of Expertise

Endobronchial Disease, Mesothelioma, Lung Metastases, Lung Cancer, Thymoma

Research Program

Cancer Signaling and Microenvironment

Distinctions

Treatment Philosophy

I decided to stay at Fox Chase Cancer Center after completing my fellowship here because I believe in the mission of this center. I believe that Fox Chase provides my patients with an environment that is not only patient friendly but also a place that great care can be delivered. I can offer many of the top clinical trials to my patients if needed and help advance the field of lung cancer therapy. With the dedicated nurses, social workers and support staff at Fox Chase I have the right team in place to help me care for my patients.

I also believe that we treat more than just a disease. I consider the patient as a whole, an individual with a disease and not just the disease. I believe in engaging patients and their families in their care to the extent that my patients allow it. I believe in a team approach to the care of patients with lung cancer and along with my colleagues in the thoracic division we can deliver the best level of care that is possible.

Lab Overview

My laboratory concentrates on the development of new cancer treatments with an emphasis on the use of immunotherapy and monoclonal antibodies. We are capable of making new monoclonal antibodies against various cancer related targets and have recently received a patent for one such antibody. In collaboration with a number of other scientists at Fox Chase and as a result of laboratory based studies conducted here, I have developed clinical trials that are ongoing for treatment of patients with lung cancer.

My collaborations with scientists outside of Fox Chase also is an important part of what I do with the aim of bringing newer and more effective immune based treatments to the clinic. My laboratory also examines patients’ tumors to try to learn why some patients respond to specific treatment while others don’t. Discovery of new or better ways of treating cancer is an important part of my activities here.

In addition to laboratory based investigations, I am active in clinical trials. My goal is to offer my patients some of the best options that are available. I believe that clinical trials, when offered appropriately, can not only help us develop the next best treatment options but also allow my patients access to potentially new and promising drugs.

In addition I am actively involved in lung cancer screening and research involving potential preventative measures with the hope of detecting lung cancer early and preventing recurrences of this disease.

Educational Background

Chief Fellow, Hematology-Oncology, Fox Chase Cancer Center, Philadelphia, PA
Resident, Graduate Hospital, Philadelphia, PA
DO, Philadelphia College of Osteopathic Medicine, 1996

Certifications

American Board of Internal Medicine - Medical Oncology

Memberships

National Comprehensive Cancer Network (NCCN)
- BI Afatinib Combination Therapy Committee
- Research Working Group
- Non-Small Cell Lung Cancer/Malignant Committee
- Pleural Mesothelioma/Thymomas Committee
- Thymic Carcinomas Panel
American Association for Cancer Research
American Society of Clinical Oncology
American Society of Hematology
NCCN thoracic committee
ECOG thoracic core committee

Honors & Awards

Philadelphia Magazine Top Doctors 2023-24

Monsignor Joseph Garvin

Lung Cancer

At 76, I’m in my 27th year as the pastor of Saint Christopher Church, a Roman Catholic parish in Northeast Philadelphia. Recently, you might say I had an experience of biblical proportions.

VIEW PATIENT STORY

Dan Sullivan

Lung Cancer

Sometimes I think that my timing was just incredible. If I had been diagnosed with cancer a few years earlier, my prognosis would have looked much different than it does today—especially if I had not gone to Fox Chase!

VIEW PATIENT STORY

Research Interests

Monoclonal Antibody, Targeted Therapy, Immunotherapy, Cancer Vaccine

Selected Publications

Borghaei H., Redman M.W., Kelly K., Waqar S.N., Robert F., Kiefer G.J., Stella P.J., Minichiello K., Gandara D.R., Herbst R.S., Papadimitrakopoulou V.A., Swog s1400a (nct02154490): A phase ii study of durvalumab for patients with previously treated stage iv or recurrent squamous cell lung cancer (lung-map sub-study). Clin Lung Cancer. 22(3): 178-186, 2021.PMC8686189. https://www.ncbi.nlm.nih.gov/pubmed/33358401.

Borghaei H., Gettinger S., Vokes E.E., Chow L.Q.M., Burgio M.A., de Castro Carpeno J., Pluzanski A., Arrieta O., Frontera O.A., Chiari R., Butts C., Wójcik-Tomaszewska J., Coudert B., Garassino M.C., Ready N., Felip E., García M.A., Waterhouse D., Domine M., Barlesi F., Antonia S., Wohlleber M., Gerber D.E., Czyzewicz G., Spigel D.R., Crino L., Eberhardt W.E.E., Li A., Marimuthu S.,Brahmer J., Five-year outcomes from the randomized, phase iii trials checkmate 017 and 057: Nivolumab versus docetaxel in previously treated non-small-cell lung cancer. J Clin Oncol. 39(7): 723-733 2021.PMC8078445. https://www.ncbi.nlm.nih.gov/pubmed/33449799.

Judd J., Abdel Karim N., Khan H., Naqash A.R., Baca Y., Xiu J., VanderWalde A.M., Mamdani H., Raez L.E., Nagasaka M., Pai S.G., Socinski M.A., Nieva J.J., Kim C., Wozniak A.J., Ikpeazu C., de Lima Lopes G., Jr., Spira A.I., Korn W.M., Kim E.S., Liu S.V., Borghaei H., Characterization of kras mutation subtypes in non-small cell lung cancer. Mol Cancer Ther. 20(12): 2577-2584, 2021. https://www.ncbi.nlm.nih.gov/pubmed/34518295.

Borghaei H, Langer CJ, Gadgeel S, Papadimitrakopoulou VA, Patnaik A, Powell SF, Gentzler RD, Martins RG, Stevenson JP, Jalal SI, Panwalkar A, Chih-Hsin Yang J, Gubens M, Sequist LV, Awad MM, Fiore J, Saraf S, Keller S, Gandhi L. 24-Month Overall Survival From KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin With or Without Pembrolizumab As First-Line Therapy for Advanced Nonsquamous Non-Small-Cell Lung Cancer. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2018. PubMed

Borghaei H, Alpaugh K, Hedlund G, Forsberg G, Langer C, Rogatko A, Hawkins R, Dueland S, Lassen U, Cohen RB. Phase I dose escalation, pharmacokinetic and pharmacodynamic study of naptumomab estafenatox alone in patients with advanced cancer and with docetaxel in patients with advanced non-small-cell lung cancer. J Clin Oncol. 2009;27:4116-23. PubMed

Borghaei H, Alpaugh RK, Bernardo P, Palazzo IE, Dutcher JP, Venkatraj U, Wood WC, Goldstein L, Weiner LM. Induction of adaptive Anti-HER2/neu immune responses in a Phase 1B/2 trial of 2B1 bispecific murine monoclonal antibody in metastatic breast cancer (E3194): A Trial Coordinated by the Eastern Cooperative Oncology Group. J Immunother. 2007;30:455-467. PubMed

Hossein Borghaei, Barry Jones, Chris Kiritsy, Jack H Lai and William Bachovchin. Overcoming the KRAS resistance mechanism by augmenting antibody-dependent cellular cytotoxicity. Colorectal Cancer, 2012, 1(4), 273-275.

Mateo J, Berlin J, de Bono JS, Cohen RB, Keedy V, Mugundu G, Zhang L, Abbattista A, Davis C, Gallo Stampino C, Borghaei H. A first-in-human study of the anti-α5β1 integrin monoclonal antibody PF-04605412 administered intravenously to patients with advanced solid tumors. Cancer Chemother Pharmacol. 2014 Sep 12. PubMed

Jalal SI, Hanna N, Zon R, Masters GA, Borghaei H, Koneru K, Badve S, Prasad N, Somaiah N, Wu J, Yu Z, Einhorn L. Phase I Study of Amrubicin and Cyclophosphamide in Patients With Advanced Solid Organ Malignancies: HOG LUN 07-130.Am J. Clin Oncol. 2014, Dec 10. PubMed

Moran T, Felip E, Keedy V, Borghaei H, Shepherd FA, Insa A, Brown H, Fitzgerald T, Sathyanarayanan S, Reilly JF, Mauro D, Hsu K, Yan L, Johnson DH. Activity of dalotuzumab, a selective anti-IGF1R antibody, in combination with erlotinib in unselected patients with Non-small-cell lung cancer: a phase I/II randomized trial. Exp Hematol Oncol. 2014 Nov 7;3(1):26. doi: 10.1186/2162-3619-3-26. PubMed

... Expand

Additional Publications

Dr. Borghaei on PubMed

The following ratings and reviews are based on verified feedback collected from independently administered patient experience surveys. The ratings and comments submitted by patients reflect their own views and opinions. Patient identities are withheld to ensure confidentiality and privacy. Learn more about our Patient Experience Ratings.